Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argenx Se ( (ARGX) ) has issued an announcement.
On February 26, 2026, Argenx reported positive topline Phase 3 results from its ADAPT OCULUS trial of subcutaneous VYVGART in adults with ocular myasthenia gravis, the first registrational study focused specifically on this under-served form of the disease. The trial met its primary endpoint, showing statistically significant improvement in patient-reported ocular symptoms versus placebo, with meaningful reductions in diplopia and ptosis and a safety profile consistent with prior studies.
Argenx said the data will support a planned supplemental biologics application to U.S. regulators to expand the VYVGART label into ocular myasthenia gravis, potentially broadening use of its core asset and reinforcing its positioning in the myasthenia gravis treatment landscape. The results underscore a significant unmet need in ocular MG, and, if approved, could extend targeted therapy access to a wider segment of MG patients and strengthen Argenx’s neuromuscular franchise.
The most recent analyst rating on (ARGX) stock is a Buy with a $1008.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.
Spark’s Take on ARGX Stock
According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.
Argenx Se’s strong financial performance and bullish technical indicators are the primary drivers of its high stock score. The company’s robust revenue growth and strategic advancements in its pipeline are significant positives. However, the high valuation and operational challenges in cash flow generation slightly temper the overall score.
To see Spark’s full report on ARGX stock, click here.
More about Argenx Se
Argenx SE is a global immunology company listed on Euronext and Nasdaq that develops targeted therapies for severe autoimmune diseases. Its lead franchise, VYVGART, is approved for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, with a growing focus on expanding indications within neuromuscular disorders.
Average Trading Volume: 343,746
Technical Sentiment Signal: Buy
Current Market Cap: $51.91B
For detailed information about ARGX stock, go to TipRanks’ Stock Analysis page.